Sort
48,018 grants matching “immunotherapy”
DEVELOPING NOVEL STRATEGIES TO UNCOUPLE IMMUNOTHERAPY-INDUCED AUTOIMMUNITY FROM ANTITUMOR IMMUNITY
$376,596University Of Western Australia · · FY2022 · Defense Health Agency
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD
$376,590Dat Quoc Tran · University Of Texas Hlth Sci Ctr Houston · R01 · FY2014 · HL
Lymph Node Alterations in Cancer
$376,557M Alanna Ruddell · Fred Hutchinson Cancer Research Center · R01 · FY2010 · CA
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity
$376,557Xiaoliu Zhang · University Of Houston · R01 · FY2023 · CA
Functions of Hopx in immune tolerance in a model of Multiple Sclerosis
$376,543Daniel Hawiger · Saint Louis University · R01 · FY2016 · AI
MyD88-independent resistance to Toxoplasma in the intestine
$376,528Eric Y Denkers · University Of New Mexico · R01 · FY2018 · AI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$376,492Ann Richmond · Vanderbilt University · R01 · FY2020 · CA
Combining c-Myc inhibitor and SHetA2 for cervical cancer: A promising low-to-no toxicity therapeutic strategy
$376,490Rajani Rai · University Of Oklahoma Hlth Sciences Ctr · R21 · FY2025 · CA
Functions of Hopx in immune tolerance in a model of Multiple Sclerosis
$376,476Daniel Hawiger · Saint Louis University · R01 · FY2017 · AI
Mechanisms and consequences of iNKT cell anergy
$376,459Luc Van Kaer · Vanderbilt University · R01 · FY2008 · AI
Mechanisms and consequences of iNKT cell anergy
$376,459Luc Van Kaer · Vanderbilt University · R01 · FY2009 · AI
RNase H2 is a novel therapeutic target in triple negative breast cancer
$376,433Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$376,433Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
EFFECTOR AND MEMORY ANTIMALARIA CD8+ CELL RESPONSES
$376,431New York University School Of Medicine · R01 · FY2000 · AI
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$376,428Jinming Gao · Ut Southwestern Medical Center · R01 · FY2020 · CA
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$376,428Jinming Gao · Ut Southwestern Medical Center · R01 · FY2018 · CA
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$376,428Jinming Gao · Ut Southwestern Medical Center · R01 · FY2021 · CA
Adenovirus as a Vector for Gene Therapy
$376,408Patrick Hearing · State University New York Stony Brook · R01 · FY2009 · AI
Adenovirus as a Vector for Gene Therapy
$376,408Patrick Hearing · State University New York Stony Brook · R01 · FY2008 · AI
MyD88-independent resistance to Toxoplasma in the intestine
$376,394Eric Y Denkers · University Of New Mexico · R01 · FY2019 · AI
Gene Transfer and Somatic Cell Enginerring
$376,325Isabelle Riviere · Sloan-Kettering Inst Can Research · P30 · FY2024 · CA
Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma
$376,317Guang Peng · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Laboratory and Clinical studies on T-cells recognizing NSCLC
$376,312James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
APOBEC3 Proteins in HIV Restriction
$376,290Reuben S Harris · University Of Minnesota · R37 · FY2015 · AI
Amelioration of recurrent herpes keratitis
$376,271Patrick M Stuart · Washington University · R01 · FY2006 · EY